USP and Phlow Partner to Validate Continuous Manufacturing Processes

December 15, 2022

The United States Pharmacopeia (USP) and Phlow have teamed up to develop a new lab that will certify and validate pharmaceutical continuous manufacturing processes to facilitate the supply of U.S.-manufactured essential medicines.

Richmond, Va.-based Phlow manufactures active pharmaceutical ingredients (API) and finished pharmaceutical products using continuous flow technology.

The alliance will facilitate Phlow’s application of ‘flow’ chemistry and other continuous advanced manufacturing processes to produce ingredients that enable domestic manufacturing of essential medicines that “have been or are at risk of being in shortage thereby contributing to a more resilient medicines supply chain,” the partners said.

Under the agreement, the methods resulting from the partnership will be shared with other domestic generics manufacturers.

View today's stories